Ajanta pharma reported numbers in line with market expectation for Q1FY2022 by Mr. Yash Gupta, Angel Broking Ltd
Below is quote on Ajanta pharma reported numbers in line with market expectation for Q1FY2022 by Mr. Yash Gupta, Equity Research Associate, Angel Broking Ltd
Ajanta pharma reported numbers in line with market expectation for Q1FY2022. Revenue from operation was up by 12% which is above the expectation, company has reported a dip in EBITDA margins, and reported EBITDA of ₹220 crores. Domestic market growth is back on track and reported domestic growth of 32% is in line with the industry growth. The company has reported export growth of 6%, US generics reported growth of 13% despite the dip in growth reported by other domestic pharma companies due to price erosion in US market.
Company has a robust pipeline for US generic business, we expect US business and Domectic business to continue their momentum in the next quarter. We have a positive view on Ajanta Pharma.
Above views are of the author and not of the website kindly read disclaimer
